Figure 1. Kaplan’s survival function in months by renal function. CKD: chronic kidney disease; PFS: progression-free survival.
| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website https://www.thejh.org |
Original Article
Volume 12, Number 5, October 2023, pages 201-207
The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
Figures
Table
| Characteristics | No-CKD (n = 108) | CKD (n = 16) |
|---|---|---|
| aEight patients did not have staging documented. bSeven patients did not have cytogenetics documented/performed. Cytogenetics and disease status were classified according to the International Myeloma Working Group (IMWG) criteria. ASCT: autologous stem cell transplantation; CKD: chronic kidney disease; ISS: International Staging System. | ||
| Age, years, median (range) | 60 (37 - 75) | 64 (48 - 77) |
| Sex, n (%) | ||
| Male | 69 (64) | 8 (50) |
| Female | 39 (36) | 8 (50) |
| Ethnicity, n (%) | ||
| White | 93 (86) | 12 (75) |
| Black | 13 (12) | 4 (25) |
| Other | 2 (2) | 0 |
| ISS stagea, n, (%) | ||
| I | 24 (22) | 0 |
| II | 40 (37) | 5 (31) |
| III | 26 (24) | 11 (69) |
| Paraprotein, n (%) | ||
| Immunoglobulin G | 67 (62) | 10 (63) |
| Non-immunoglobulin G | 41 (38) | 6 (37) |
| Cytogeneticsb, n (%) | ||
| High | 30 (28) | 7 (44) |
| Standard | 72 (67) | 8 (50) |
| History of prior ASCT, n (%) | ||
| Yes | 4 (4) | 0 |
| No | 104 (96) | 16 (100) |
| Disease status prior to ASCT, n (%) | ||
| Stringent complete response | 0 | 0 |
| Complete response | 10 (9) | 4 (25) |
| Very good partial response | 30 (28) | 2 (13) |
| Partial response | 64 (59) | 10 (62) |
| Stable | 2 (2) | 0 |
| Progressive | 2 (2) | 0 |
| Stage of CKD | ||
| 1 | 0 | 0 |
| 2 | 0 | 0 |
| 3 | 0 | 12 (75) |
| 4 | 0 | 3 (19) |
| 5 | 0 | 1 (6) |
| Melphalan dose (mg/m2) | ||
| 200 | 104 (96) | 11 (69) |
| 140 | 4 (4) | 5 (31) |